[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Jakov |
| 2. | Perekonnanimi | Šlik |
| 3. | Töökoht | Tartu Ulikooli Psuhhiaatriakliinik Ottawa Ulikooli Psuhhiaatriakateeder |
| 4. | Ametikoht | Vanemteadur Assotsieerunud professor Arevushairete Programmi kliiniline direktor |
| 5. | Sünniaeg | 08.09.1961 (päev.kuu.aasta) |
| 6. | Haridus | 1978 Tallinna 25. keskkool 1985 Tartu Ulikooli arstiteaduskond, ravi eriala |
| 7. | Teenistuskäik | 09/2003 - : Kliiniline direktor, Arevushairete programm, Kuninglik Ottawa Haigla, Ottawa, Ontario, Kanada; 09/2003 - : Assotsieerunud Professor, Psuhhiaatria kateeder, Ottawa Ulikool, Ottawa, Ontario, Kanada; 01/2003 - : Vanemteadur, Tartu Ulikooli psuhhiaatriakliinik; 01/2000 - 12/2002: Une ja Arevushairete uuringuteosakonna juhataja, Tartu Ulikooli Kliinikumi psuhhiaatriakliinik; 09/1999 - 12/2002: Vanemassistent, Tartu Ulikooli psuhhiaatriakliinik 09/1998 - 08/2003: Arst-psuhhiaater, Tartu Ukilooli KLiinikumi psuhhiaatriakliinik 02/1995 - 08/1998: Assistent, Tartu Ulikooli psuhhiaatriakliinik 01/1990 - 10/1994: Arst-psuhhiaater, Tartu Ukilooli KLiinikumi psuhhiaatriakliinik 03/1986 – 12/1990: vanemlaborant ja nooremteadur, Kliinilise ja eksperimentaalse psuhhofarmakoloogia laboratoorium, UMPI, Tartu Ulikool. |
| 8. | Teaduskraad | Meditsiinidoktor |
| 9. | Teaduskraadi välja andnud asutus, aasta |
Tartu Ulikool 1999 |
| 10. | Tunnustused | 2004: ECNP-ACNP Exchange Poster Award at the 17th European College of Neuropsychopharmacology Congress, Stockholm, Sweden; 2003: Poster Award at the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic; 2000: Poster award at the 22nd International College of Neuropsychopharmacology Congress, Brussels, Belgium; 2000: Research grant award, Faculty of Health Sciences, University of Linköping, Sweden; 1998: Fellowship Award, European College of Neuropsychopharmacology; 1998: New Investigator Award, National Institute of Mental Health, USA; 1997: Best presentation award by a trainee, Royal Ottawa Hospital, University of Ottawa; 1991: Scholarship from the Norwegian Psychiatric Association at the Department of Psychiatry, University of Oslo, Norway. |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
Rahvusvaheline Neuropsuhhofarmakoloogia Kolleegium, liige; Kanada Neuropsuhhofarmakoloogia Kolleegium, liige; Eesti Psuhhiaatrite Selts, liige; Eesti Kognitiivse ja Kaitumisteraapia Assotsiatsioon, liige; Kanada Arstide Assotsiatsioon ja Ontario Arstide Assotsiatsioon, liige; Psuhhiaatria residentuuri juhendaja, Tartu Ulikooli arstiteaduskond 200-2003; Tartu A-Uhingu juhatuse esimees 1999-2003. |
| 12. | Juhendamisel kaitstud väitekirjad |
Eduard Maron, PhD, 2004, juh. Jakov Šlik, Veiko Vasar. Serotonin function in panic diosrder. Tartu Ulikool |
| 13. | Teadustöö põhisuunad | Arevushairete neurobioloogia ja ravi Koletsustokiniini osa psuhhikahairetes Hindamismeetodid psuhhiaatrias |
| 14. | Jooksvad grandid | Raviresistentsete arevushairete biogeneetilised aspektid - Ottawa Ulikooli Vaimse Tervise Uurigute Fond, 2003-2007. |
| 15. | Teaduspublikatsioonid |
Maron E, Lang A, Tasa G, Liivlaid L, Tõru I, Must A, Vasar V, Shlik J. Associations between serotonin related gene polymorphisms and panic disorder. International Journal of Neuropsychopharmacology 2005;8:261-266. Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J. Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics 2005;15:17-24. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 2005; Epub ahead of print. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Research: Neuroimaging 2004;132:173-181. Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. European Archives of Psychiatry and Clinical Neuroscience 2004;254:392-396. Maron E, Tõru I, Vasar V, Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Journal of Psychopharmacology 2004;18:194-199. Shlik J, Maron E, Tõru I, Aluoja A, Vasar V. Citalopram challenge in social anxiety disorder. International Journal of Neuropsychopharmacology 2004;7:177-82. Swain J, Koszycki D, Shlik J, Bradwejn J. Pharmacological challenge agents in anxiety. In: Anxiety Disorders. Nutt DJ, Ballenger JC (Eds.), Blackwell Science, Oxford 2003. Shlik J, Zhou Y, Koszycki D, Vaccarino JF, Bradwejn J. Effect of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. Journal of Psychopharmacology 1999;13:385-390. Shlik J, Koszycki D, Bradwejn J. Decrease in short-term memory function induced by CCK-4 in healthy volunteers. Peptides 1998;6:969-975. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine responses to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry and Neuroscience 1997;22:332-40 Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders: role in aethiology and potential of receptor antagonists in therapy. CNS Drugs 1997;8:134-52. |
viimati muudetud: 06.10.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Jakov |
| 2. | Surname | Šlik |
| 3. | Institution | University of Tartu, Department of Psychiatry University of Ottawa, Department of Psychiatry Royal Ottawa Hospital |
| 4. | Position | Senior scientist Associate Professor Clinical Director, Anxiety Disorders Program |
| 5. | Date of birth | 08.09.1961 (day.month.year) |
| 6. | Education | 1978 Tallinn 25th high school 1985 University of Tartu, Faculty of Medicine, physician diploma |
| 7. | Research and professional experience |
09/2003 – date: Clinical Director, Anxiety Disorders Program, Royal Ottawa Hospital, Ottawa, Ontario, Canada; 09/2003 – date: Associate Professor, Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 01/2003 – date: Senior scientist, Department of Psychiatry, University of Tartu, Tartu, Estonia; 01/2000 – 12/2002: Head, Sleep and Anxiety Disorders Research Unit, Clinic of Psychiatry, Tartu University Clinics, Tartu, Estonia; 09/1999 – 12/2002: Senior assistant professor, Department of Psychiatry, University of Tartu, Tartu, Estonia; 09/1998 – 08/2003: Staff psychiatrist, Clinic of Psychiatry, Tartu University Clinics, Tartu, Estonia; 02/1995 – 08/1998: Assistant professor, Department of Psychiatry, University of Tartu; Tartu, Estonia; 01/1990 – 10/1994: Staff psychiatrist, Tartu Psychiatric Hospital, Tartu, Estonia; 03/1986 – 12/1990: Research associate, Laboratory of Clinical and Experimental Psychopharmacology, University of Tartu, Tartu, Estonia. |
| 8. | Academic degree | Doctor of Medical Sciences (Ph.D.) |
| 9. | Dates and sites of earning the degrees |
University of Tartu, Tartu, Estonia; 1999 |
| 10. | Honours/awards | 2004: ECNP-ACNP Exchange Poster Award at the 17th European College of Neuropsychopharmacology Congress, Stockholm, Sweden; 2003: Poster Award at the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic; 2000: Poster award at the 22nd International College of Neuropsychopharmacology Congress, Brussels, Belgium; 2000: Research grant award, Faculty of Health Sciences, University of Linköping, Sweden; 1998: Fellowship Award, European College of Neuropsychopharmacology; 1998: New Investigator Award, National Institute of Mental Health, USA; 1997: Best presentation award by a trainee, Royal Ottawa Hospital, University of Ottawa; 1991: Scholarship from the Norwegian Psychiatric Association at the Department of Psychiatry, University of Oslo, Norway. |
| 11. | Research-administrative experience |
International College of Neuropsychopharmacology (CINP), fellow; Canadian College of Neuropsychopharmacology (CCNP), fellow; Canadian Medical Association and Ontario Medical Associations, member; Estonian Psychiatric Association, member; Estonian Association of Cognitive and Behavioural Therapies, member; Estonian Association of Biological Psychiatry, member. Director of postgraduate education program in psychiatry, Faculty of Medicine, University of Tartu, 2000-2003; Chairman of the Board, A-Foundation (substance dependence clinic and prevention), Tartu, Estonia, 1999-2003. |
| 12. | Supervised dissertations |
Eduard Maron, PhD, 2004, superv. Jakov Šlik, Veiko Vasar. Serotonin function in panic diosrder. Tartu Ulikool |
| 13. | Current research program | Neurobiology and treatment of anxiety disorders Cholecystokinin role in psychiatric diosrders Assessment methods in psychiatry |
| 14. | Current grant funding | Biogenetic aspects of treatment resistant anxiety diosrders - University of Ottawa Mental Health Research Fund, 2003-2007. |
| 15. | List of most important publications |
Maron E, Lang A, Tasa G, Liivlaid L, Tõru I, Must A, Vasar V, Shlik J. Associations between serotonin related gene polymorphisms and panic disorder. International Journal of Neuropsychopharmacology 2005;8:261-266. Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J. Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics 2005;15:17-24. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 2005; Epub ahead of print. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Research: Neuroimaging 2004;132:173-181. Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. European Archives of Psychiatry and Clinical Neuroscience 2004;254:392-396. Maron E, Tõru I, Vasar V, Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Journal of Psychopharmacology 2004;18:194-199. Shlik J, Maron E, Tõru I, Aluoja A, Vasar V. Citalopram challenge in social anxiety disorder. International Journal of Neuropsychopharmacology 2004;7:177-82. Swain J, Koszycki D, Shlik J, Bradwejn J. Pharmacological challenge agents in anxiety. In: Anxiety Disorders. Nutt DJ, Ballenger JC (Eds.), Blackwell Science, Oxford 2003. Shlik J, Zhou Y, Koszycki D, Vaccarino JF, Bradwejn J. Effect of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. Journal of Psychopharmacology 1999;13:385-390. Shlik J, Koszycki D, Bradwejn J. Decrease in short-term memory function induced by CCK-4 in healthy volunteers. Peptides 1998;6:969-975. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine responses to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry and Neuroscience 1997;22:332-40 Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders: role in aethiology and potential of receptor antagonists in therapy. CNS Drugs 1997;8:134-52. |
last updated: 06.10.2005
[ sulge aken ]